Biontech Se ADR (BNTX) Stock Price, Quote & News

Company Profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin a...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 6131 9084

Fax: 49 6131 9084

Website: www.biontech.de

Address:

An der Goldgrube 12, Mainz, Germany

taxplanr Aug. 20 at 6:46 PM

$BNTX doesn't their ceo like to talk about unpublished results like $MRNA

0 · Reply

StocktwitsNews Aug. 20 at 6:16 PM

ARCT Defies mRNA Selloff And Extends Rally As Moderna, BioNTech Shares Pull Back $ARCT $MRNA $BNTX https://stocktwits.com/news/equity/markets/arct-defies-m-rna-selloff-and-extends-rally-as-moderna-bio-n-tech-shares-pull-back/cZYIDxYRJZZ

0 · Reply

cubie Aug. 20 at 5:05 PM

$MRNA peas in a pod $BNTX barely down there and $TEM been nice.green all day

0 · Reply

eightytwentie Aug. 20 at 3:46 PM

$BNTX man just a bunch of bots pumping and peddling other shyt stocks lately on this board

0 · Reply

NodeInvestmentGroup Aug. 20 at 2:52 PM

$BNTX remains a major biotechnology company focused on innovative medicines and next-generation healthcare technologies. AERT’s operating income jumped 310% year over year to $3.4 million, highlighting substantial improvement in core profitability.

0 · Reply

WavefrontSecurities Aug. 20 at 2:51 PM

0 · Reply

SmartSigma Aug. 20 at 2:28 PM

$BNTX I think the most impressive part of the Q2 release is that they did this without massive dilution they are growing organically from sales not from issuing shares that kind of clean growth is very rare and it makes the valuation look even more absurd

0 · Reply

clubb Aug. 20 at 2:19 PM

$BNTX bullish but still to early to buy

0 · Reply

tkstockpicker Aug. 20 at 1:49 PM

$BNTX added

0 · Reply

DonCorleone77 Aug. 20 at 11:54 AM

$MRNA $MRK $BNTX Leerink says cancer vaccine win should sustain Merck momentum into fall Leerink notes Merck (MRK) and Moderna (MRNA) announced the top-line recurrence-free survival and distant metastasis-free survival success of the Phase 3 INTerpath-001 study of INT plus pembrolizumab in completed resected Stage IIB to IV melanoma. With this "unexpected Phase 3 success" of intismeran autogene combined with pembrolizumab in adjuvant melanoma, the firm expects positive investor reaction that will sustain momentum for Merck into the fall. The result is also positive, in Leerink's view, for cancer vaccine-levered stocks, but this no longer BioNTech (BNTX) and the firm expects any BioNTech gains today to fade as investors absorb the poor read-through. The firm has an Outperform rating on Merck.

0 · Reply

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

2026-08-19T16:05:37.000Z - 1 day ago

BioNTech rises 20.3%

2026-08-19T14:00:12.000Z - 1 day ago

BioNTech rises 21.6%

2026-08-05T14:23:35.000Z - 15 days ago

BioNTech price target lowered to $130 from $135 at Evercore ISI

2026-08-05T11:05:37.000Z - 15 days ago

BioNTech price target raised to $142 from $138 at Canaccord

2026-08-05T10:35:32.000Z - 15 days ago

BioNTech price target lowered to $125 from $130 at Citi

Aug 4, 2026, 8:00 AM EDT - 16 days ago

BioNTech SE Earnings Call Transcript: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 16 days ago

BioNTech SE Earnings release: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 16 days ago

BioNTech SE Slides: Q2 2026

Aug 4, 2026, 7:12 AM EDT - 16 days ago

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

PFE

Aug 4, 2026, 7:02 AM EDT - 16 days ago

BioNTech lowers 2026 sales outlook as COVID vaccine demand softens

2026-08-04T10:50:25.000Z - 16 days ago

BioNTech cuts FY26 revenue view to EUR 1.6B-EUR 1.9B from EUR 2B-EUR 2.3B

Aug 4, 2026, 6:45 AM EDT - 16 days ago

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

Aug 3, 2026, 5:29 AM EDT - 17 days ago

BioNTech says Sobi's Oelkers will replace Sahin as CEO

2026-08-03T09:05:08.000Z - 17 days ago

BioNTech CEO Ugur Sahin to depart, Guido Oelkers to succeed

Aug 3, 2026, 5:00 AM EDT - 17 days ago

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

2026-07-29T20:42:19.000Z - 21 days ago

EC authorizes Pfizer, BioNTech XFG-adapted COVID-19 vaccine in EU

PFE

Jul 29, 2026, 4:30 PM EDT - 21 days ago

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

PFE

Jul 21, 2026, 6:45 AM EDT - 4 weeks ago

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

2026-07-08T11:40:53.000Z - 6 weeks ago

BioNTech price target lowered to $119 from $126 at Morgan Stanley

Jul 3, 2026, 1:51 AM EDT - 6 weeks ago

BioNTech held buyer talks over four German sites set to close, Handelsblatt reports

Jun 17, 2026, 2:38 AM EDT - 2 months ago

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

MRNA

2026-05-31T21:45:07.000Z - 2 months ago

BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial

BMY

May 30, 2026, 2:15 PM EDT - 2 months ago

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

May 27, 2026, 11:07 AM EDT - 3 months ago

This Biotech's Cancer Portfolio Could End Its Rough Patch

May 22, 2026, 5:00 AM EDT - 3 months ago

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

May 15, 2026, 4:15 PM EDT - 3 months ago

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

May 15, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Transcript: AGM 2026

May 7, 2026, 6:45 AM EDT - 3 months ago

BioNTech Announces New ADS Repurchase Program

May 6, 2026, 7:44 AM EDT - 3 months ago

Germany says vaccine supply secure despite BioNTech production loss

May 5, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Slides: Q1 2026

May 5, 2026, 7:26 AM EDT - 3 months ago

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

May 5, 2026, 6:47 AM EDT - 3 months ago

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

May 5, 2026, 6:45 AM EDT - 3 months ago

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

Apr 21, 2026, 5:35 PM EDT - 4 months ago

Two experimental drugs showed striking early results against pancreatic cancer

RVMD

Apr 21, 2026, 6:45 AM EDT - 4 months ago

BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026

Apr 11, 2026, 7:00 AM EDT - 4 months ago

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

Apr 1, 2026, 11:39 AM EDT - 5 months ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

PFE

Mar 24, 2026, 6:45 AM EDT - 5 months ago

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

Mar 10, 2026, 2:48 PM EDT - 5 months ago

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 10, 2026, 1:29 PM EDT - 5 months ago

One simple reason why BioNTech stock is a raging buy on today's crash

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Slides: Q4 2025

Mar 10, 2026, 7:40 AM EDT - 5 months ago

Scientists behind COVID-19 vaccine will depart BioNTech

Mar 10, 2026, 7:18 AM EDT - 5 months ago

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.

Mar 10, 2026, 6:50 AM EDT - 5 months ago

BioNTech Cofounders to Leave to Form New Company

Mar 10, 2026, 6:49 AM EDT - 5 months ago

BioNTech's founding couple Sahin, Tuereci to leave to set up new venture

Mar 10, 2026, 6:45 AM EDT - 5 months ago

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Mar 10, 2026, 6:33 AM EDT - 5 months ago

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

Feb 24, 2026, 6:45 AM EST - 6 months ago

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

Feb 19, 2026, 1:25 PM EST - 6 months ago

BioNTech sues Moderna for patent infringement over COVID-19 shots

MRNA

Jan 28, 2026, 8:00 AM EST - 7 months ago

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

Jan 13, 2026, 5:15 PM EST - 7 months ago

BioNTech SE Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 5:15 PM EST - 7 months ago

BioNTech SE Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 AM EST - 7 months ago

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 10:00 AM EST - 7 months ago

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

Dec 18, 2025, 4:45 AM EST - 8 months ago

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

Dec 9, 2025, 7:00 AM EST - 9 months ago

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

BMY

Dec 6, 2025, 3:30 PM EST - 9 months ago

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Dec 3, 2025, 9:01 AM EST - 9 months ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

CVAC

Dec 1, 2025, 3:50 PM EST - 9 months ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

MRNA NVAX PFE

Dec 1, 2025, 12:35 PM EST - 9 months ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

MRNA NVAX PFE

Nov 26, 2025, 7:30 AM EST - 9 months ago

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Nov 13, 2025, 5:20 PM EST - 9 months ago

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

PFE

Nov 13, 2025, 8:17 AM EST - 10 months ago

BioNTech says collaboration with Pfizer remains unchanged

PFE

Nov 11, 2025, 9:00 AM EST - 10 months ago

BioNTech SE Transcript: R&D Day

Nov 11, 2025, 9:00 AM EST - 10 months ago

BioNTech SE Slides: R&D Day

Nov 3, 2025, 8:00 AM EST - 10 months ago

BioNTech SE Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:00 AM EST - 10 months ago

BioNTech SE Earnings release: Q3 2025

Nov 3, 2025, 8:00 AM EST - 10 months ago

BioNTech SE Slides: Q3 2025

Nov 3, 2025, 6:47 AM EST - 10 months ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:45 AM EST - 10 months ago

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Oct 28, 2025, 7:45 AM EDT - 10 months ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 27, 2025, 7:45 AM EDT - 10 months ago

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

taxplanr Aug. 20 at 6:46 PM

$BNTX doesn't their ceo like to talk about unpublished results like $MRNA

0 · Reply

StocktwitsNews Aug. 20 at 6:16 PM

0 · Reply

cubie Aug. 20 at 5:05 PM

$MRNA peas in a pod $BNTX barely down there and $TEM been nice.green all day

0 · Reply

eightytwentie Aug. 20 at 3:46 PM

$BNTX man just a bunch of bots pumping and peddling other shyt stocks lately on this board

0 · Reply

NodeInvestmentGroup Aug. 20 at 2:52 PM

0 · Reply

WavefrontSecurities Aug. 20 at 2:51 PM

0 · Reply

SmartSigma Aug. 20 at 2:28 PM

0 · Reply

clubb Aug. 20 at 2:19 PM

$BNTX bullish but still to early to buy

0 · Reply

tkstockpicker Aug. 20 at 1:49 PM

$BNTX added

0 · Reply

DonCorleone77 Aug. 20 at 11:54 AM

0 · Reply

GordoHLYK13 Aug. 20 at 10:09 AM

$BNTX $CAPR $IBRX $IGC $SLS “$MRNA could be an intriguing strategic beneficiary if $IGC’s IGC-AD1 Phase 2 data validate a new cannabinoid-based approach to Alzheimer’s agitation—potentially opening the door to broader CNS opportunities, partnerships, or acquisition interest around innovative treatments.”

0 · Reply

GordoHLYK13 Aug. 20 at 8:17 AM

$IGC $SLS $IBRX $CAPR $BNTX CALMA Phase 2 Alzheimer's trial is within just six randomizations of closing enrollment, setting up top-line data readout in Q4

0 · Reply

CarrieSpence437 Aug. 20 at 7:39 AM

$BNTX $LPLA $EIX $PBA $NMR BioNTech remains focused on oncology and vaccine development, LPL Financial benefits from advisor and asset growth, Edison International provides regulated utility exposure, Pembina Pipeline benefits from Canadian energy infrastructure, and NMR remains execution-dependent. I'm watching clinical milestones, market levels, power demand, energy volumes, and liquidity.

0 · Reply

SethHarling755 Aug. 20 at 7:02 AM

$BNTX $UPST $MCD $AMTM BioNTech advances oncology and immunotherapy programs, Upstart remains sensitive to consumer-credit conditions, McDonald's benefits from global restaurant demand, and AMTM remains execution-dependent. I'm watching clinical milestones, credit performance, same-store sales, contracts, and margins.

0 · Reply

TNNStockAnalysisNews Aug. 20 at 5:47 AM

Top Stock Gainers Today (August 19, 2026): $MRNA — Closed at $174.38, Up an Almost Unbelievable 176.97% $BNTX — Closed Near $111.55-$112.17, Up as Much as 22.9% $MRK — Trading Up to $152.20, Gaining as Much as 12.6% to a Record High $KC — Rising 10.6% on a Surprise Break-Even Quarter $NVAX — Climbing More Than 7% on Sector-Wide Vaccine Momentum https://truthsandnews.com/markets/top-stock-gainers-today-august-19-2026-moderna-explodes

0 · Reply

I_Value_Life Aug. 20 at 5:44 AM

$BNTX sold my last lot here, cutting my losses..

0 · Reply

eightytwentie Aug. 20 at 3:48 AM

$BNTX this is Biontech all year baby

0 · Reply

Bullish_Wicks Aug. 20 at 3:42 AM

$MRVI $BNTX Best ticker heading into tomorrow PWCM! This Crypto play is setting up for a monster move, insanely small float and fits the theme! Make sure to put PWCM on ur watch bulls!

0 · Reply

Swift_Trades Aug. 20 at 3:25 AM

$MRNA Similar upcoming potential catalysts... 😁 BioNTech ($BNTX) BNT113 mRNA immunotherapy for HPV16+ PD-L1+ head/neck cancer; Phase 3 interim PFS data expected later 2026. Geron ($GERN) imetelstat (telomerase inhibitor) for R/R myelofibrosis; Phase 3 OS interim analysis due 2H 2026. Kodiak ($KOD) Zenkuda/KSI-501 for wet AMD; Phase 3 DAYBREAK topline Sept 2026. Rank by likelihood of positive readout: 1. BNTX (Fast Track + prior signals, mRNA parallel to MRNA). 2. GERN (strong Phase 2 OS data). 3. KOD.

1 · Reply

mollielatham Aug. 20 at 12:06 AM

$BNTX has always been higher than MRNA---PLUS more $ and more drugs in phase 3---

0 · Reply

mollielatham Aug. 20 at 12:02 AM

$BNTX cash cash cash in the bank--alot more than MRNA

0 · Reply

Spicy_Trade Aug. 19 at 11:54 PM

BioNTech SE ( $BNTX ) SpicyTrade - Daily Stock Analysis https://youtu.be/3qkRt-9yUJA?si=yiNPf-QNfvOBN4v-

0 · Reply

Market Cap	23.45B
Revenue (ttm)	3.25B
Net Income (ttm)	-1.29B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-39.59%
Debt to Equity Ratio	0.02

Volume	2,743,930
Avg Vol	1,094,116
Day's Range	N/A - N/A
Shares Out	252.88M
Stochastic %K	89%
Beta	1.27
Analysts	Strong Sell
Price Target	$123.94